Literature DB >> 9516065

Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes.

A Hübler1, K Abendroth, T Keiner, W Stöcker, E Kauf, G Hein, G Stein.   

Abstract

We report on a 33-year-old male patient with generalized acquired lipodystrophy, insulin resistant diabetes mellitus and acanthosis nigricans (Lawrence Syndrome). First probable symptoms of lipodystrophy (weight loss, shrinkage of subcutaneous fatty tissue, and loss of muscular strength) became evident three years ago, with the onset of diabetes mellitus occurring about six months later. The patient suffered from the following clinical symptoms: IDDM with increasing insulin-requirement, extreme reduction of fatty tissue, fatty liver hepatitis with elevated liver enzymes, glomerulopathy, muscular and neuropathic pains, as well as hypertriglyceridaemia. A basal C-peptide concentration is rather high. Definitely, the endogenous insulin secretion is increased. In other words, insulin resistance is documented. In an effort to identify the pathogenetic mechanisms of lipoatrophic diabetes mellitus in this patient and to develop a therapeutic strategy, antibodies against different tissues and endocrinologic regulation were investigated. It was possible to demonstrate the presence of serum autoantibodies against lipocytes of the subcutis and other tissues, against hepatic stellate cells, together with autoantibodies against different endocrine organs. By studying the basis of diabetic abnormalities relating to the growth hormone (GH), the insulin-like growth factor (IGF) dynamics in this patient, i.e. reductions of GH, IGF-I, IGF-II, IGF-Binding protein (IGF-BP) 2 and IGF-BP 3, were detected. An immunosuppressive treatment strategy was not beneficial.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516065     DOI: 10.1055/s-0029-1211955

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  7 in total

Review 1.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

2.  Lymphoma in acquired generalized lipodystrophy.

Authors:  Rebecca J Brown; Jean L Chan; Elaine S Jaffe; Elaine Cochran; Alex M DePaoli; Jean-Francois Gautier; Cecile Goujard; Corinne Vigouroux; Phillip Gorden
Journal:  Leuk Lymphoma       Date:  2015-05-12

Review 3.  Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

Authors:  G M Behrens; M Stoll; R E Schmidt
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

4.  A case of acquired generalized lipodystrophy with cerebellar degeneration and type 2 diabetes mellitus.

Authors:  Pei-Jiuan Chao; Jack C-R Tsai; Dao-Ming Chang; Shyi-Jang Shin; Yau-Jiunn Lee
Journal:  Rev Diabet Stud       Date:  2005-02-10

Review 5.  New advances in the treatment of generalized lipodystrophy: role of metreleptin.

Authors:  Alexander J Rodriguez; Claudio A Mastronardi; Gilberto J Paz-Filho
Journal:  Ther Clin Risk Manag       Date:  2015-09-16       Impact factor: 2.423

6.  Immunological features of patients affected by Barraquer-Simons syndrome.

Authors:  Fernando Corvillo; Giovanni Ceccarini; Pilar Nozal; Silvia Magno; Caterina Pelosini; Sofía Garrido; Alberto López-Lera; Manuela Moraru; Carlos Vilches; Silvia Fornaciari; Sabrina Gabbriellini; Ferruccio Santini; David Araújo-Vilar; Margarita López-Trascasa
Journal:  Orphanet J Rare Dis       Date:  2020-01-10       Impact factor: 4.123

7.  Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy.

Authors:  Fernando Corvillo; Verónica Aparicio; Alberto López-Lera; Sofía Garrido; David Araújo-Vilar; María P de Miguel; Margarita López-Trascasa
Journal:  Front Immunol       Date:  2018-09-19       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.